{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T18:40:51Z","timestamp":1768070451649,"version":"3.49.0"},"reference-count":166,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.clindermatol.2004.06.013","type":"journal-article","created":{"date-parts":[[2005,3,30]],"date-time":"2005-03-30T12:19:15Z","timestamp":1112185155000},"page":"182-192","source":"Crossref","is-referenced-by-count":32,"title":["The life-threatening complications of dermatologic therapies"],"prefix":"10.1016","volume":"23","author":[{"given":"Edith","family":"Orion","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagit","family":"Matz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronni","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2004.06.013_bib1","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0738-081X(02)00281-X","article-title":"Parasitic skin infestation II, scabies, pediculosis, spider bites: unapproved treatments","volume":"20","author":"Orion","year":"2002","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib2","first-page":"275","article-title":"Analysis of the prevention of post-ivermectin Loa loa encephalopathy by administration of initial low dose","volume":"60","author":"Kamgno","year":"2000","journal-title":"Med. Trop."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.4269\/ajtmh.1998.58.461","article-title":"Three probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis","volume":"58","author":"Boussinesq","year":"1998","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0140-6736(96)11094-1","article-title":"Serious reactions after mass treatment of onchocerciasis in an endemic area for Loa loa infection","volume":"350","author":"Gardon","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib5","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/S0140-6736(89)90136-0","article-title":"Side-effects of ivermectin in treatment of onchocerciasis","volume":"1","author":"Rothova","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib6","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(99)09458-1","article-title":"Scabies and pediculosis","volume":"355","author":"Cosidow","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5070\/D330M4B5KR","article-title":"Dapsone","volume":"8","author":"Wolf","year":"2002","journal-title":"Dermatol. Online J."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0300-483X(01)00360-2","article-title":"Dapsone-mediated agranulocytosis: risks, possible mechanisms and prevention","volume":"162","author":"Coleman","year":"2001","journal-title":"Toxicology"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib9","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1001\/archderm.126.7.919","article-title":"The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988","volume":"126","author":"Hornsten","year":"1990","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/bmj.317.7152.181","article-title":"Eosinophilic pneumonia induced by dapsone","volume":"317","author":"Jaffuel","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib11","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/S0025-6196(12)62479-3","article-title":"Tertracyclines, chloramphenicol, erythromycin, clindamycin, metronidazole","volume":"66","author":"Smilack","year":"1991","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib12","first-page":"158","article-title":"Toxicologic evaluation of metronidazole with particular reference to carcinogenic, mutagenic, and teratogenic potential","volume":"93","author":"Roe","year":"1983","journal-title":"Surgery"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib13","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1345\/aph.10028","article-title":"Toxic metronidazole-induced MRI changes","volume":"34","author":"Horlen","year":"2000","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib14","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/106002808201600511","article-title":"Convulsions associated with high cumulative doses of metronidazole","volume":"16","author":"Halloran","year":"1982","journal-title":"Drug Intell. Clin. Pharm."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib15","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00000441-200005000-00012","article-title":"Convulsions induced by metronidazole treatment for Clostridium difficile\u2013associated disease in chronic renal failure","volume":"319","author":"Belooseky","year":"2000","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib16","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/j.1875-9114.1982.tb03216.x","article-title":"Mental confusion in a patient treated with metronidazole\u2014a concentration-related effect?","volume":"2","author":"Schentag","year":"1982","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib17","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1176\/ajp.154.8.1170b","article-title":"Metronidazole-induced psychotic disorder","volume":"154","author":"Schreiber","year":"1997","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib18","first-page":"97","article-title":"Acute encephalopathy associated with metronidazole therapy","volume":"26","author":"Omotoso","year":"1997","journal-title":"Afr. J. Med. Sci."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib19","first-page":"252","article-title":"Metronidazole as a probable cause of severe liver injury","volume":"49","author":"Bjornsson","year":"2002","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib20","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/clinids\/13.6.1213","article-title":"Metronidazole-induced acute pancreatitis","volume":"13","author":"Corey","year":"1991","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib21","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/0016-5085(90)91111-I","article-title":"How often does metronidazole induce pancreatitis?","volume":"98","author":"Friedman","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib22","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1345\/aph.10021","article-title":"Metronidazole-associated pancreatitis","volume":"34","author":"Sura","year":"2000","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib23","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00000433-199612000-00013","article-title":"Sudden death due to metronidazole\/ethanol interaction","volume":"17","author":"Cina","year":"1996","journal-title":"Am. J. Forensic Med. Pathol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1383-5742(02)00007-8","article-title":"Is metronidazole carcinogenic?","volume":"511","author":"Bendesky","year":"2002","journal-title":"Mutat. Res."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.5694\/j.1326-5377.1988.tb120578.x","article-title":"Haemolytic-uremic syndrome after treatment with metronidazole","volume":"149","author":"Powell","year":"1988","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib26","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00007611-198303000-00038","article-title":"Serum sickness associated with metronidazole","volume":"76","author":"Weart","year":"1983","journal-title":"South Med. J."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib27","first-page":"213","article-title":"Metronidazole-induced asthma","volume":"33","author":"Bedi","year":"1991","journal-title":"Indian J. Chest Dis. Allied Sci."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib28","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jama.260.2.184","article-title":"Pneumonitis caused by metronidazole","volume":"260","author":"Kriestenson","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0750-7658(85)80252-5","article-title":"Drug-induced agranulocytosis. Discussion of the responsibility of metronidazole","volume":"4","author":"Martin","year":"1985","journal-title":"Ann. Fr. Anesth. Reanim."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00002018-200022010-00004","article-title":"A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis","volume":"22","author":"Gupta","year":"2000","journal-title":"Drug Saf."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib31","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/0002-9343(94)90141-4","article-title":"Fatal acute hepatic necrosis due to fluconazole","volume":"96","author":"Jacobson","year":"1994","journal-title":"Am. J. Med."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib32","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1128\/AAC.43.8.1955","article-title":"Safety and tolerability of fluconazole in children","volume":"43","author":"Novelli","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib33","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1159\/000239592","article-title":"Safety evaluation of chronic fluconazole therapy. Fluconazole Pan-American Study Group","volume":"43","author":"Stevens","year":"1997","journal-title":"Chemotherapy"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib34","first-page":"165","article-title":"Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration","volume":"91","author":"Guillaume","year":"1996","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib35","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/archinte.151.5.1020","article-title":"Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome","volume":"151","author":"Munoz","year":"1991","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib36","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1592\/phco.22.17.1632.34129","article-title":"Probable case of torsades de pointes induced by fluconazole","volume":"22","author":"Khazan","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib37","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1345\/aph.10210","article-title":"Fluconazole-induced torsade de pointes","volume":"35","author":"Tholakanahalli","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib38","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1177\/030006059202000607","article-title":"Agranulocytosis during treatment with fluconazole","volume":"20","author":"Murakami","year":"1992","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib39","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1592\/phco.20.5.484.35058","article-title":"Fluconazole-induced agranulocytosis with eosinophilia","volume":"20","author":"Wong-Beringer","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib40","first-page":"517","article-title":"Fluconazole-induced agranulocytosis","volume":"49","author":"Chuncharunee","year":"1994","journal-title":"Therapie"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib41","doi-asserted-by":"crossref","first-page":"899","DOI":"10.7326\/0003-4819-113-11-899_1","article-title":"Fluconazole-induced thrombocytopenia","volume":"113","author":"Agarwal","year":"1990","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib42","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000247261","article-title":"Fluconazole-induced toxic epidermal necrolysis in a patient with human immunodeficiency virus infection","volume":"187","author":"Azon-Masoliver","year":"1993","journal-title":"Dermatology"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib43","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/0140-6736(91)90643-4","article-title":"Angio-oedema after fluconazole","volume":"338","author":"Abbott","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib44","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/bmj.302.6788.1341-b","article-title":"Anaphylactic reaction after oral fluconazole","volume":"302","author":"Neuhaus","year":"1991","journal-title":"BMJ"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib45","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0140-6736(91)90112-3","article-title":"Stevens-Johnson syndrome after fluconazole","volume":"338","author":"Gussenhoven","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib46","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/00003246-200103000-00039","article-title":"Possible association between high-dose fluconazole and adrenal insufficiency in critically ill patients","volume":"29","author":"Albert","year":"2001","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib47","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00007691-200010000-00022","article-title":"Fluconazole-induced convulsions at serum trough concentrations of approximately 80 microg\/mL","volume":"22","author":"Matsumoto","year":"2000","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib48","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/jac\/26.4.561","article-title":"Adverse events associated with itraconazole in 189 patients on chronic therapy","volume":"26","author":"Tucker","year":"1990","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib49","first-page":"6","article-title":"Update on the safety of itraconazole pulse therapy in onychomycosis and dermatomycosis","volume":"11","author":"Gupta","year":"2001","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib50","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1439-0507.1989.tb02295.x","article-title":"Toxicological profile and safety evaluation of antifungal azole derivatives","volume":"32","author":"Van Cauteren","year":"1989","journal-title":"Mycoses"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib51","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1592\/phco.22.9.697.34072","article-title":"Itraconazole and fluconazole and certain rare, serious adverse events","volume":"22","author":"Brandbury","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib52","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s10227-001-0048-3","article-title":"Hepatic safety of itraconazole","volume":"6","author":"Gupta","year":"2002","journal-title":"J. Cutan. Med. Surg."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib53","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1179\/acb.2001.055","article-title":"Hepatotoxicity related to itraconazole: report of three cases","volume":"56","author":"Adriaenssens","year":"2001","journal-title":"Acta Clin. Belg."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib54","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1111\/j.1572-0241.1999.01623.x","article-title":"Severe cholestasis related to itraconazole for treatment of onychomycosis","volume":"94","author":"Tawalkar","year":"1999","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib55","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/thorax.57.8.749","article-title":"Profound adrenal suppression secondary to treatment with low dose inhaled steroids and itraconazole in allergic bronchopulmonary aspergillosis in cystic fibrosis","volume":"57","author":"Parmar","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib56","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0190-9622(08)81838-5","article-title":"Risk\/benefit ratio of modern antifungal therapy: focus on hepatic reactions","volume":"29","author":"Hay","year":"1993","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib57","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.11150\/kansenshogakuzasshi1970.69.1413","article-title":"A case of itraconazole-induced hypokalemia with pulmonary aspergilloma","volume":"69","author":"Yamamoto","year":"1995","journal-title":"Kansenshogaku Zasshi"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib58","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/0163-4453(93)96203-3","article-title":"Ventricular fibrillation secondary to itraconazole induced hypokalemia","volume":"26","author":"Nelson","year":"1993","journal-title":"J. Infect."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib59","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/S0140-6736(00)04891-1","article-title":"Congestive heart failure associated with itraconazole","volume":"357","author":"Ahmed","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib60","first-page":"1127","article-title":"Pancreatitis ascribed to the use of itraconazole","volume":"145","author":"Langers","year":"2001","journal-title":"Ned. Tijdsschr. Geneeskd."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib61","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1176\/appi.psy.44.3.260","article-title":"Itraconazole-induced delirium","volume":"44","author":"Mittal","year":"2003","journal-title":"Psychosomatics"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib62","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1046\/j.1365-2230.1998.00321.x","article-title":"Hepatitis associated with terbinafine therapy: three case reports and a review of the literature","volume":"23","author":"Gupta","year":"1998","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib63","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00000441-200305000-00008","article-title":"Terbinafine-associated hepatotoxicity","volume":"325","author":"Ajit","year":"2003","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib64","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/00042737-200109000-00021","article-title":"Terbinafine-induced hepatic dysfunction","volume":"13","author":"Chambers","year":"2001","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib65","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJM199904223401617","article-title":"Terbinafine and fulminant hepatic failure","volume":"340","author":"Agarwal","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib66","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1572-0241.1998.00459.x","article-title":"Terbinafine hepatotoxicity: case report and review of the literature","volume":"93","author":"Fernandes","year":"1998","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib67","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1067\/mjd.2001.117520","article-title":"Reversible agranulocytosis associated with oral terbinafine in a pediatric patient","volume":"45","author":"Aguilar","year":"2001","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib68","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0190-9622(98)70208-7","article-title":"Severe neutropenia associated with oral terbinafine therapy","volume":"38","author":"Gupta","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib69","first-page":"996","article-title":"Cerebral and renal toxicity of acyclovir in a patient treated for meningoencephalitis","volume":"18","author":"Da Conceicao","year":"1999","journal-title":"Ann. Fr. Anesth. Reanim."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib70","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/00007611-199911000-00010","article-title":"A cute renal insufficiency due to oral acyclovir in a man with sickle cell trait","volume":"92","author":"Lawson","year":"1999","journal-title":"South Med. J."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib71","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0002-9343(99)00041-8","article-title":"Crystal-induced acute renal failure","volume":"106","author":"Perazella","year":"1999","journal-title":"Am. J. Med."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib72","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1345\/aph.1A297","article-title":"Acyclovir-induced crystalluria","volume":"36","author":"Blossom","year":"2002","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib73","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1345\/aph.17135","article-title":"Acyclovir- and gancyclovir-induced neurotoxicity","volume":"32","author":"Ernst","year":"1998","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib74","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00134-002-1254-1","article-title":"Acyclovir-induced coma in a young patient without preexisting renal impairment","volume":"28","author":"Delerme","year":"2002","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib75","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1053\/jinf.2002.1119","article-title":"Encephalopathy induced by oral acyclovir in a patient with normal renal function","volume":"46","author":"Vander","year":"2003","journal-title":"J. Infect."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib76","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/0310057X0002800309","article-title":"Acyclovir induced coma in the intensive care unit","volume":"28","author":"Rajan","year":"2000","journal-title":"Anaesth. Intensive Care"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib77","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF03167726","article-title":"Coma secondary to acyclovir neurotoxicity","volume":"170","author":"Loughrey","year":"2001","journal-title":"Ir. J. Med. Sci."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib78","first-page":"1614","article-title":"Hypotension in acyclovir therapy","volume":"87","author":"Wolters","year":"1998","journal-title":"Schweiz. Rundsch. Med. Prax."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib79","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/clinids\/20.6.1557","article-title":"Acyclovir-induced neutropenia in an infant with herpes simplex encephalitis","volume":"20","author":"Feder","year":"1995","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib80","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/clinids\/21.4.1038","article-title":"Stevens-Johnson syndrome induced by treatment with acyclovir","volume":"21","author":"Fazal","year":"1995","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib81","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/106002809703100211","article-title":"Valacyclovir","volume":"31","author":"Acosta","year":"1997","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib82","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5414\/CNP58168","article-title":"Valacyclovir neurotoxicity in a patient with end-stage renal disease treated with continuous ambulatory peritoneal dialysis","volume":"58","author":"Okada","year":"2002","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib83","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000046241","article-title":"Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study","volume":"21","author":"Izzedine","year":"2001","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib84","first-page":"7","article-title":"Valacyclovir study stopped\u2014worse survival","volume":"17","author":"James","year":"1995","journal-title":"AIDS Treat. News"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib85","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0190-9622(81)70065-3","article-title":"Antimalarials","volume":"4","author":"Koranda","year":"1981","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib86","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0950-3579(05)80294-8","article-title":"Drug-induced myopathies","volume":"5","author":"Le Quintrec","year":"1991","journal-title":"Baillieres Clin. Rheumatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib87","first-page":"2927","article-title":"Hydroxychloroquine neuromyotoxicity","volume":"27","author":"Stein","year":"2000","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib88","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/archderm.97.2.163","article-title":"Hydroxychloroquine-induced agranulocytosis","volume":"97","author":"Chernof","year":"1968","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib89","first-page":"310","article-title":"Thrombocytopenia secondary to hydroxychloroquine","volume":"11","author":"Caminal Montero","year":"1994","journal-title":"Ann. Med. Interne"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib90","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/gut.35.4.569","article-title":"Fulminant hepatic failure secondary to hydroxychloroquine","volume":"35","author":"Makin","year":"1994","journal-title":"Gut"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib91","first-page":"140","article-title":"Chloroquine and hydroxychloroquine: side effect profile of important therapeutic drugs","volume":"42","author":"Ochsendorf","year":"1991","journal-title":"Hautarzt"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib92","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/ajem.2001.25774","article-title":"Treatment of hydroxychloroquine overdose","volume":"19","author":"Marquardt","year":"2001","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib93","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1067\/mjd.2001.113717","article-title":"Uses and complications of isotretinoin therapy","volume":"45","author":"Ellis","year":"2001","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib94","first-page":"79","article-title":"Acute pancreatitis secondary to isotretinoin-induced hyperlipidemia","volume":"95","author":"Jamshidi","year":"2002","journal-title":"J. Okla. State Med. Assoc."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib95","first-page":"1855","article-title":"Marked hyperlipidemia and pancreatitis associated with isotretinoin therapy","volume":"87","author":"McCarter","year":"1992","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib96","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/ndt\/12.6.1299a","article-title":"Renal impairment induced by isotretinoin","volume":"12","author":"Pavese","year":"1997","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib97","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/ndt\/15.6.923","article-title":"Nephrotic syndrome associated with isotretinoin","volume":"15","author":"van Oers","year":"2000","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib98","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1067\/mjd.2001.118233","article-title":"Suicide, depression, and isotretinoin: is there a casual link?","volume":"45","author":"Jacobs","year":"2001","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib99","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1067\/mjd.2002.12","article-title":"Isotretinoin (Accutane) and serious psychiatric adverse events","volume":"48","author":"O'Connell","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib100","first-page":"2","article-title":"Isotretinoin induced rhabdomyolysis? A case report","volume":"5","author":"Trauner","year":"1999","journal-title":"Dermatol. Online J."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib101","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1046\/j.1365-2133.2003.05209_1.x","article-title":"Two new adverse effects of isotretinoin","volume":"148","author":"Charalabopoulos","year":"2003","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib102","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0190-9622(08)80257-5","article-title":"Long-term safety of retinoid therapy","volume":"27","author":"Vahlquist","year":"1992","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib103","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2340\/0001555575332","article-title":"Pseudoallergic hepatitis after a single intake of 10 mg acitretin (Neotigason) for treatment of psoriasis pustulosa","volume":"75","author":"Blum","year":"1995","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib104","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1572-0241.2002.05581.x","article-title":"Severe cholestatic hepatitis in a patient taking acitretin","volume":"97","author":"Kreiss","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib105","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0168-8278(90)90111-4","article-title":"Severe hepatotoxic reaction with progression to cirrhosis after use of a novel retinoid (acitretin)","volume":"11","author":"van Ditzhuijsen","year":"1990","journal-title":"J. Hepatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib106","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1345\/aph.1C090","article-title":"Acitretin-associated thrombotic stroke","volume":"36","author":"Royer","year":"2002","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib107","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5070\/D36XW860XK","article-title":"Respiratory distress with acitretin, reversal by corticosteroids","volume":"7","author":"Cuhadaroglu","year":"2001","journal-title":"Dermatol. Online J."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib108","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2165\/00002018-200225030-00004","article-title":"Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept","volume":"25","author":"Fleischmann","year":"2002","journal-title":"Drug Saf."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib109","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1521-6926(03)00043-4","article-title":"Retinoic acid syndrome: manifestations, pathogenesis, and treatment","volume":"16","author":"Larson","year":"2003","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib110","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00002018-200326010-00003","article-title":"Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis","volume":"16","author":"Mikuls","year":"2003","journal-title":"Drug Saf."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib111","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00128071-200001010-00003","article-title":"Risk-benefit assessment of methotrexate in the treatment of severe psoriasis","volume":"1","author":"Kuijpers","year":"2000","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib112","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0190-9622(98)70508-0","article-title":"Methotrexate in psoriasis: consensus conference","volume":"38","author":"Roenigk","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib113","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1155\/1996\/213596","article-title":"Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risk from obesity, diabetes and alcohol consumption during long-term follow-up","volume":"10","author":"Malatjalian","year":"1996","journal-title":"Can. J. Gastroenterol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib114","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0889-857X(05)70365-3","article-title":"Methotrexate hepatotoxicity","volume":"23","author":"West","year":"1997","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib115","first-page":"477","article-title":"Pancytopenia and severe cytopenia induced by low-dose methotrexate. Eight case-reports and a review of one hundred cases from the literature (with twenty-four deaths)","volume":"62","author":"Berthelot","year":"1995","journal-title":"Rev. Rheum. Engl. Ed."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib116","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0889-857X(05)70368-9","article-title":"Does methotrexate increase the risk of infection or malignancy?","volume":"23","author":"Kanik","year":"1997","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib117","first-page":"2249","article-title":"Two cases of methotrexate induced lymphomas in rheumatoid arthritis: an association with increased serum Ig E","volume":"26","author":"Kono","year":"1999","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib118","first-page":"810","article-title":"Reversible methotrexate associated lymphoproliferative disease evolving into Hodgkin's disease","volume":"27","author":"Moseley","year":"2000","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib119","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/00002018-199920060-00002","article-title":"Lymphoma in patients with rheumatoid arthritis: what is the evidence of a link with methotrexate?","volume":"20","author":"Georgescu","year":"1999","journal-title":"Drug Saf."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib120","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3109\/03009749609065644","article-title":"Methotrexate update","volume":"25","author":"Kremer","year":"1996","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib121","first-page":"352","article-title":"Hypersensitivity interstitial pneumopathy and ulcero-hemorrhagic rectocolitis: role of methotrexate","volume":"56","author":"Bohon","year":"1993","journal-title":"Acta Gastroenterol. Belg."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib122","first-page":"1766","article-title":"Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis","volume":"22","author":"Van der Veen","year":"1995","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib123","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/BF02238967","article-title":"Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of 5 cases and review of the literature","volume":"16","author":"Salaffi","year":"1997","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib124","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0889-857X(05)70366-5","article-title":"Methotrexate pulmonary toxicity","volume":"23","author":"Cannon","year":"1997","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib125","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1046\/j.1468-3083.2000.00058.x","article-title":"Methotrexate in psoriasis: 26 years experience with low-dose long-term treatment","volume":"14","author":"Haustein","year":"2000","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib126","first-page":"1050","article-title":"Methotrexate-related neurotoxicity in the treatment of childhood acute lymphoblastic leukemia","volume":"4","author":"Shuper","year":"2002","journal-title":"Isr. Med. Assoc. J."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib127","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00002018-200124010-00003","article-title":"Anticancer drug-induced kidney disorders","volume":"24","author":"Kintzel","year":"2001","journal-title":"Drug Saf."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib128","first-page":"111","article-title":"Treatment with low dose methotrexate in rheumatoid arthritis and risk factors for severe complications","volume":"52","author":"Berthelot","year":"1997","journal-title":"Therapie"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib129","first-page":"392","article-title":"Ciclosporin","volume":"129","author":"Doutre","year":"2002","journal-title":"Ann. Dermatol. Venereol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib130","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.4065\/71.12.1182","article-title":"Cyclosporine in the treatment of dermatologic disease: an update","volume":"71","author":"Lim","year":"1996","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib131","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1093\/ndt\/12.10.2054","article-title":"Cyclosporin nephrotoxicity following cardiac transplantation","volume":"12","author":"Woolfson","year":"1997","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib132","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/00075198-200112000-00003","article-title":"Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies","volume":"7","author":"Olayei","year":"2001","journal-title":"Curr. Opin. Crit. Care"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib133","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/1389200023337964","article-title":"Interaction of cyclosporine A and the rennin-angiotensin system: new perspectives","volume":"3","author":"Lassila","year":"2002","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib134","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2165\/00002018-199920050-00004","article-title":"Cyclosporin-induced hypertension: incidence, pathogenesis and management","volume":"20","author":"Taler","year":"1999","journal-title":"Drug Saf."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib135","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00062752-200109000-00004","article-title":"Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome","volume":"8","author":"Medina","year":"2001","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib136","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s004150050360","article-title":"Cyclosporine neurotoxicity: a review","volume":"246","author":"Gijtenbeek","year":"1999","journal-title":"J. Neurol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib137","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00002826-199903000-00001","article-title":"Cyclosporine A neurotoxicity among bone marrow transplant recipients","volume":"22","author":"Shah","year":"1999","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib138","first-page":"45","article-title":"Cyclosporine-induced white and grey matter central nervous system lesions in a pediatric renal transplant patient","volume":"2","author":"Jeruss","year":"1998","journal-title":"Pediatr. Transplant."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib139","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00002018-200225130-00003","article-title":"Comparative tolerability of systemic treatments for plaque-type psoriasis","volume":"25","author":"McClure","year":"2002","journal-title":"Drug Saf."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib140","first-page":"203","article-title":"Cutaneous T-cell lymphoma in a cardiac transplant recipient","volume":"28","author":"McMullan","year":"2001","journal-title":"Tex. Heart Inst. J."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib141","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1097\/00007890-199911150-00009","article-title":"Tuberculosis in renal transplant recipients","volume":"68","author":"Sayiner","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib142","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1046\/j.1529-8019.2000.00034.x","article-title":"Second and third generation antihistamines in the treatment of urticaria","volume":"13","author":"Ellis","year":"2000","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib143","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0002-9149(99)00124-1","article-title":"Cardiovascular safety of fexofenadine HCl","volume":"83","author":"Pratt","year":"1999","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib144","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1046\/j.1365-2222.1999.0290s3163.x","article-title":"The systemic safety of fexofenadine HCl","volume":"29","author":"Mason","year":"1999","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib145","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archderm.134.1.80","article-title":"Dermatological uses of high-dose intravenous immunoglobulins","volume":"134","author":"Jolles","year":"1998","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib146","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s00415-003-1085-1","article-title":"Side effects of intravenous immunoglobulins in neurological autoimmune disorders\u2014a prospective study","volume":"250","author":"Stangel","year":"2003","journal-title":"J. Neurol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib147","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1212\/WNL.47.3.674","article-title":"Complications of intravenous immune globulin treatment in neurologic disease","volume":"47","author":"Brannagan","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib148","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/000331970205300117","article-title":"Intravenous immunoglobulin-related acute coronary syndrome and coronary angiography in idiopathic thrombocytopenic purpura\u2014a case report and literature review","volume":"53","author":"Crouch","year":"2002","journal-title":"Angiology"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib149","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1592\/phco.22.17.1638.34125","article-title":"Thrombotic complications after intravenous immunoglobulin therapy in two patients","volume":"22","author":"Emerson","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib150","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archderm.139.8.991","article-title":"Stroke and deep vein thrombosis complicating intravenous immunoglobulin infusions","volume":"139","author":"Katz","year":"2003","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib151","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/bmj.324.7345.1056","article-title":"Intravenous immunoglobulin increases the risk of thrombotic events","volume":"324","author":"Gottlieb","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib152","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1046\/j.1365-2141.2002.03741.x","article-title":"Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin","volume":"118","author":"Hayakawa","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib153","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-4362.1984.tb05696.x","article-title":"Thalidomide therapy for inflammatory dermatoses","volume":"23","author":"Grosshans","year":"1984","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib154","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5070\/D35FK5W0QV","article-title":"A review of thalidomide's history and current dermatological applications","volume":"9","author":"Perri","year":"2003","journal-title":"Dermatol. Online J."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib155","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0190-9622(96)90122-X","article-title":"Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses","volume":"35","author":"Tseng","year":"1996","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib156","first-page":"231","article-title":"Thalidomide and its impact in dermatology","volume":"174","author":"Stirling","year":"1988","journal-title":"Semin. Cutan. Med. Surg."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib157","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1345\/aph.1D003","article-title":"Thalidomide-induced sinus bradycardia","volume":"37","author":"Kaur","year":"2003","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib158","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1634\/theoncologist.6-1-34","article-title":"Interferon in oncological practice: review of interferon biology, clinical applications and toxicities","volume":"6","author":"Jonasch","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.clindermatol.2004.06.013_bib159","first-page":"3","article-title":"A perspective on the clinical effectiveness and tolerance of interferon-alpha","volume":"25","author":"Borden","year":"1998","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib160","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood","year":"1966","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib161","first-page":"9","article-title":"Safety profile of interferon-alfa therapy","volume":"25","author":"Weiss","year":"1998","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib162","first-page":"39","article-title":"Mood and cognitive side effects of interferon alfa therapy","volume":"25","author":"Valentine","year":"1998","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib163","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1089\/jir.1993.13.349","article-title":"Effects of cytokines on the pituitary-adrenal axis in cancer patients","volume":"13","author":"Nolten","year":"1993","journal-title":"J. Interferon Res."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib164","first-page":"469","article-title":"Incidence, pathoetiology and treatment of interferon-alpha induced neuro-psychiatric side effects","volume":"71","author":"Schafer","year":"2003","journal-title":"Fortschr. Neuro. Psychiatr."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib165","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s535-002-8133-3","article-title":"Reactivation of sarcoidosis during interferon therapy","volume":"37","author":"Li","year":"2002","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.clindermatol.2004.06.013_bib166","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000057631","article-title":"Immune-mediated complications during interferon therapy in hematological patients","volume":"107","author":"Raanani","year":"2002","journal-title":"Acta Haematol."}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X04001130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X04001130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T12:00:31Z","timestamp":1706097631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X04001130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":166,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0738081X04001130"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2004.06.013","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}